FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
Authors
Keywords
-
Journal
Biomolecules
Volume 9, Issue 11, Pages 668
Publisher
MDPI AG
Online
2019-10-31
DOI
10.3390/biom9110668
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
- (2019) Rashmi R. Shah et al. DRUG SAFETY
- Pharmacokinetic study of osimertinib in cancer patients with mild or moderate hepatic impairment
- (2019) Enrique Grande et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Development and validation of a sensitive LC-MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients
- (2019) Shaoxing Guan et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib
- (2019) A J Schoenfeld et al. ANNALS OF ONCOLOGY
- Erlotinib treatment induces cytochrome P450 3A activity in non‐small cell lung cancer patients
- (2019) Anna Svedberg et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib
- (2019) G.D. Marijn Veerman et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer
- (2019) Filippo de Marinis et al. Future Oncology
- Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
- (2018) D Westover et al. ANNALS OF ONCOLOGY
- The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib
- (2018) Karthick Vishwanathan et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy
- (2018) Enriqueta Felip et al. Clinical Lung Cancer
- Development and validation of a sensitive LC–MS/MS method for simultaneous determination of eight tyrosine kinase inhibitors and its application in mice pharmacokinetic studies
- (2018) Yu He et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- High throughput routine determination of 17 tyrosine kinase inhibitors by LC–MS/MS
- (2018) Camille Merienne et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients
- (2018) Rafael Reis et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Osimertinib in EGFR Mutation–Positive Advanced NSCLC
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin
- (2018) R. Donald Harvey et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Osimertinib versus standard-of-care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset
- (2018) Byoung Chul Cho et al. Journal of Thoracic Oncology
- A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing
- (2018) Patrick H. Lizotte et al. Cancer Immunology Research
- The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events
- (2018) Yoshihiko Sakata et al. Asia-Pacific Journal of Clinical Oncology
- An Accurate and Effective Method for Measuring Osimertinib by UPLC-TOF-MS and Its Pharmacokinetic Study in Rats
- (2018) Song-Tao Dong et al. MOLECULES
- Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer
- (2017) Antonio Rossi et al. Expert Opinion on Drug Metabolism & Toxicology
- Development and Validation of a Rapid and Sensitive LC-MS/MS Method for the Pharmacokinetic Study of Osimertinib in Rats
- (2017) Shan Xiong et al. JOURNAL OF AOAC INTERNATIONAL
- Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
- (2017) James Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Nasser Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers
- (2017) Karthick Vishwanathan et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non–Small Cell Lung Cancer
- (2017) Pei Ni Ding et al. Journal of Thoracic Oncology
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS
- (2017) Huu H. Huynh et al. THERAPEUTIC DRUG MONITORING
- Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats
- (2017) Osamu Yasumuro et al. XENOBIOTICA
- Simultaneous determination of six tyrosine kinase inhibitors in human plasma using HPLC-Q-Orbitrap mass spectrometry
- (2017) Mao-Wei Ni et al. Bioanalysis
- Simultaneous Quantification of Erlotinib, Gefitinib, and Imatinib in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry
- (2017) A Chahbouni et al. THERAPEUTIC DRUG MONITORING
- A highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study
- (2016) Adnan A. Kadi et al. BIOMEDICAL CHROMATOGRAPHY
- An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma
- (2016) Ali S. Abdelhameed et al. BIOMEDICAL CHROMATOGRAPHY
- Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies
- (2016) David Planchard et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring EGFR Mutations
- (2016) Yoshitaka Zenke et al. Clinical Lung Cancer
- Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC–MS/MS and its application to a pharmacokinetics study
- (2016) Nan Zheng et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Liquid chromatography–tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid–liquid extraction
- (2016) Rolf W. Sparidans et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Liquid chromatography–tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma
- (2016) Johannes J.M. Rood et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Liquid chromatographytandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O desmethyl metabolites of erlotinib and gefitinib in human plasma
- (2016) Rolf W. Sparidans et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
- (2016) Ethan Basch et al. JOURNAL OF CLINICAL ONCOLOGY
- Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
- (2016) Glenwood Goss et al. LANCET ONCOLOGY
- Osimertinib making a breakthrough in lung cancer targeted therapy
- (2016) Haijun Zhang OncoTargets and Therapy
- EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction
- (2016) Nesaretnam Barr Kumarakulasinghe et al. Oncotarget
- Pharmacokinetics of Gefitinb: Roles of Drug Metabolizing Enzymes and Transporters
- (2016) Han Shuyan et al. Current Drug Delivery
- Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors
- (2016) Shuhang Wang et al. Frontiers of Medicine
- A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole
- (2016) Katharina Gunzer et al. SpringerPlus
- Factors affecting therapeutic compliance: A review from the patient’s perspective
- (2016) Shu-Chuen Li Therapeutics and Clinical Risk Management
- Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up
- (2015) D. E. Peterson et al. ANNALS OF ONCOLOGY
- Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals
- (2015) Heidemarie Kletzl et al. ANTI-CANCER DRUGS
- Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer
- (2015) Hideki Hayashi et al. BIOMEDICAL CHROMATOGRAPHY
- Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib
- (2015) John F. Deeken et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Management of egfr tki–induced dermatologic adverse events
- (2015) B. Melosky et al. Current Oncology
- A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours
- (2015) A. Suder et al. EUROPEAN JOURNAL OF CANCER
- A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma
- (2015) Anna Svedberg et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
- (2014) Rajesh V. Lalla et al. CANCER
- The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects
- (2014) Marta Hamilton et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir
- (2014) Sven Wind et al. CLINICAL DRUG INVESTIGATION
- Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer
- (2014) Gillian M. Keating DRUGS
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
- (2014) Barbara Melosky et al. Frontiers in Oncology
- First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
- (2013) J-Y Douillard et al. BRITISH JOURNAL OF CANCER
- Comparison of the diagnostic performances of diffusion parameters in diffusion weighted imaging and diffusion tensor imaging of breast lesions
- (2013) Ozgur Cakir et al. EUROPEAN JOURNAL OF RADIOLOGY
- A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry
- (2013) Nielka P. van Erp et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS
- (2013) Irina Andriamanana et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both
- (2013) Nobuyuki Katakami et al. JOURNAL OF CLINICAL ONCOLOGY
- Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma WithEGFRMutations
- (2013) James Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development
- (2013) Gillian S. Smelick et al. MOLECULAR PHARMACEUTICS
- Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
- (2012) M. Takeda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Quantitative determination of erlotinib andO-desmethyl erlotinib in human EDTA plasma and lung tumor tissue
- (2012) NAG Lankheet et al. Bioanalysis
- Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS
- (2011) Stéphane Bouchet et al. CLINICA CHIMICA ACTA
- Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer
- (2011) V. Hirsh Current Oncology
- A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma
- (2011) Lionel Faivre et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography–tandem mass spectrometry
- (2011) Ling-Zhi Wang et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
- (2011) Mario E. Lacouture et al. SUPPORTIVE CARE IN CANCER
- Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain
- (2010) Rafael Rosell et al. Clinical & Translational Oncology
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer
- (2010) Yoichi Nakamura et al. Journal of Thoracic Oncology
- The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib
- (2010) Yuan-Yuan Zhao et al. MEDICAL ONCOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors
- (2009) A. Osio et al. BRITISH JOURNAL OF DERMATOLOGY
- Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers
- (2009) Andrew N. Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started